AstraZeneca's (AZN) "Overweight" Rating Reaffirmed at JPMorgan Chase & Co.

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "overweight" rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a report released on Wednesday, MarketBeat.com reports.

Several other research analysts also recently commented on AZN. Shore Capital reissued a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. Berenberg Bank restated a "buy" rating and set a GBX 140 ($1.77) target price on shares of AstraZeneca in a report on Monday, January 27th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, AstraZeneca has an average rating of "Moderate Buy" and an average price target of GBX 7,542.80 ($95.30).

AstraZeneca Price Performance

AZN stock traded up GBX 118 ($1.49) during trading on Wednesday, hitting £117.08 ($147.92). 2,754,515 shares of the stock traded hands, compared to its average volume of 25,206,791. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market cap of £225.27 billion, a price-to-earnings ratio of 32.09, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a one year low of GBX 9,670 ($122.17) and a one year high of £133.88 ($169.15). The company has a 50 day simple moving average of £109.99 and a 200 day simple moving average of £114.67.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.